136 results about "Proteomic Profiling" patented technology

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

The invention provides methods, reagents and systems for incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to enrich the proteins or fragments thereof in a number of uses, such as proteomic analysis, imaging of diseased tissues / cells, etc.

Here the inventors describe a tumor classifier based on protein expression. Also disclosed is the use of proteomics to construct a highly accurate artificial neural network (ANN)-based classifier for the detection of an individual tumor type, as well as distinguishing between six common tumor types in an unknown primary diagnosis setting. Discriminating sets of proteins are also identified and are used as biomarkers for six carcinomas. A leave-one-out cross validation (LOOCV) method was used to test the ability of the constructed network to predict the single held out sample from each iteration with a maximum predictive accuracy of 87% and an average predictive accuracy of 82% over the range of proteins chosen for its construction.

Predicting response to adjuvant therapy or predicting disease progression in breast cancer is realized by (1) first obtaining a breast cancer test sample from a subject; (2) second obtaining clinicopathological data from said breast cancer test sample; (3) analyzing the obtained breast cancer test sample for presence or amount of (a) one or more molecular markers of hormone receptor status, one or more growth factor receptor markers, (b) one or more tumor suppression / apoptosis molecular markers; and (c) one or more additional molecular markers both proteomic and non-proteomic that are indicative of breast cancer disease processes; and then (4) correlating (a) the presence or amount of said molecular markers and, with (b) clinicopathological data from said tissue sample other than the molecular markers of breast cancer disease processes. A kit of (1) a panel of antibodies; (2) one or more gene amplification assays; (3) first reagents to assist said antibodies with binding to tumor samples; (4) second reagents to assist in determining gene amplification; permits, when applied to a breast cancer patient's tumor tissue sample, (A) permits observation, and determination, of a numerical level of expression of each individual antibody, and gene amplification; whereupon (B) a computer algorithm, residing on a computer can calculate a prediction of treatment outcome for a specific treatment for breast cancer, or future risk of breast cancer progression.

A method of diagnosing or monitoring a condition of interest in a subject includes comparing thermograms generated using differential scanning calorimetery. A signature thermogram contains a protein composition pattern for a sample obtained from the subject. The signature thermogram is compared to a standard thermogram. Standard thermograms can include a negative standard thermogram containing a protein composition pattern associated with an absence of the condition of interest, and a positive standard thermogram containing a protein composition pattern associated with a presence of the condition of interest.

The invention provides a cell micro-array chip and a preparation method thereof and belongs to the technical field of cell chips. The cell micro-array chip is characterized by being prepared by using alginate gels; and the preparation method comprises the following steps: 1, coating a layer of sodium alginate solution on a glass plate, rapidly immerging the glass plate in a calcium chloride solution and soaking the glass plate for 5-30 minutes to form a gel template; 2, preparing a dot matrix template on which a plurality of cylinders are arranged, soaking the top ends of the cylinders in a chitosan or polylysine solution and taking out the cylinders after 5-30 minutes; 3, embossing the top ends of the cylinders on the alginate gel template and forming a complex dot matrix template through electrostatic complexation reaction; and 4, soaking the complex dot matrix template in a culture solution with cell concentration of 1*10<5>-1*10<7> and forming the alginate gel cell micro-array chip when the complex dot matrix template is cultured for 4-16 hours. The cell micro-array chip provided by the invention has the advantage of simplicity and convenience in operation and can be used for cell tissue like culturing, high throughput screening of compounds or medicines, discovery of new genes, proteomic studies and the like.

Methods of determining whether a sample includes one or more analytes, particularly proteinaceous analytes, of interest are provided. In the subject methods, an array of binding agents, where each binding agent includes an epitope binding domain of an antibody, is contacted with the sample. In many embodiments, contact occurs in the presence of a metal ion chelating polysaccharide, e.g., a pectin. Following contact, the presence of binding complexes on the array surface are detected and the resultant data is employed to determine whether the sample includes the one or more analytes of interest. Also provided are kits, systems and other compositions of matter for practicing the subject methods. The subject methods and compositions find use in a variety of applications, including proteomic applications such as protein expression analysis, e.g., differential protein expression profiling.

The invention discloses a wild ginseng protein extracting method suitable for dielectrophoresis. The method comprises the following steps of: taking wild ginseng as an experimental material, fully grinding the wild ginseng in liquid nitrogen and transferring the obtained product to a centrifuge tube; adding acetone solution precooled at the temperature of -20 DEG C into the centrifuge tube, washing sample powder for 3 times, collecting sediments by centrifugation and drying the obtained product at room temperature for 20min to obtain the crude extract of the wild ginseng protein; dissolving the crude extract of the wild ginseng protein into lysis buffer, and performing ultrasonic cell disintegration and extracting the supernate by centrifugation to obtain the high-quality solution of the wild ginseng protein. The wild ginseng protein extracting method for the dielectrophoresis is simple and fast, can obtain an electrophoresis pattern having a high repeatability and resolution, is favorable for subsequent protein identification by mass spectrographic analysis and provides a technical support for the proteomic research of the wild ginseng.

The present invention relates to processes for producing polyclonal and monoclonal antibodies to an antigen in an avian species, preferably in a chicken, using polynucleotide vaccination. The present invention also relates to processes for determining the proteomics profile of a set of pre-selected DNA sequences isolated from a bio-sample, preferably the proteomics profile of a human cDNA library. The present invention additionally relates to processes for identifying physiologically distinguishable markers associated with a physiologically abnormal bio-sample. The present invention further relates to antibody arrays, integrated databases for identification of genes and proteins, multi-functional gene expression vectors, and methods of producing and using such antibody arrays, integrated databases and multi-functional gene expression vectors.

An optical micro-array reader system includes microchip, VCSEL, microlens and detector arrays. The microchip array includes multiple sample spots to be separately analyzed. The VCSEL array is disposed to simultaneously illuminate more than one of the multiple spots. The microlens array focuses fluorescences or other optical emissions from the sample spots onto the detector array.

This invention refers to a new method for optimizing the composition of cell culture media. This new method comprises two main stages. In the first stage, a functional enviromics map is built through the joint screening of cell functions and medium factors by the execution of a specific cell culture protocol and exometabolome assays protocol. The functional enviromics map consists of a data array of intensity values of elementary cellular functions against medium factors. In the second stage, optimized cell culture medium formulations are developed that either enhance or repress target elementary cellular functions from columns of the functional enviromics map. The main advantage of this method lies in enabling metabolic engineering through the culture media composition manipulation, wherein an arbitrarily high number of cell functions are optimized through manipulation of medium factors, as opposed to previous methods, which are eminently empirical, are not cell function oriented, and require a much higher number of experiments. Furthermore, this new method is based on cost-effective exometabolome assays and does not require costly intracellular genomic or proteomic assays.

Provided herein are methods for identifying new biomarkers for various diseases using proteomics, peptidomics, metabolics, proteoglycomics, glvcomics, mass spectrometry and machine learning. The present disclosure also provides glycopeptides as biomarkers for various diseases such as cancer and autoimmune diseases.

The invention discloses a method for detecting chronic nephritis biomarkers based on salivary proteomics. The method comprises the following specific steps: sample protein extraction; determination ofthe concentration of extracted protein by using a Brad ford method; proteolysis; iTRAQ marking; vacuum refrigerated centrifugation drying; reversed phase chromatography under a high pH condition; protein analysis by using ABI-5600; mass spectral data analysis, namely when selecting a database, in case of an sequenced organism, a database for this species is directly selected, and in case of a non-sequenced organism, a database for a large-range proteome most relevant to a sample to be tested is selected; iTRAQ mass spectrometric analysis by using an ABI-5600 mass spectrometer. The method canbe used for finding out specific protein markers in chronic nephritis by using quick and reliable proteomics technology scheme, so as to establish a non-invasive, easy, convenient, fast, and practicaldetection assessment for early diagnosis and treatment, postoperative recurrence, metastasis and prognosis observation of the chronic nephritis.